Welcome to our dedicated page for Halozyme Thrp SEC filings (Ticker: HALO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Halozyme Therapeutics, Inc. (HALO) SEC filings page on Stock Titan provides access to the company’s official regulatory disclosures filed with the U.S. Securities and Exchange Commission. As a Nasdaq-listed biopharmaceutical company, Halozyme uses Forms 10-K, 10-Q and 8-K to report on its drug delivery business, collaborations, financing activities and governance matters.
Through current reports on Form 8-K, Halozyme discloses material events such as the issuance of convertible senior notes due 2031 and 2032, amendments to its revolving credit facility, entry into and completion of the Elektrofi acquisition, significant collaboration agreements, and executive appointments or transitions. These filings often include details on note terms, capped call transactions, credit covenants and merger conditions that are not fully described in press releases.
Annual reports on Form 10-K and quarterly reports on Form 10-Q (not reproduced here but referenced in 8-Ks) typically contain broader discussions of Halozyme’s ENHANZE, Hypercon and MDASE technology portfolios, risk factors, royalty and collaboration structures, and overall financial condition. Investors use these filings to understand how platform licensing, proprietary products and acquisitions contribute to the company’s long-term strategy.
Stock Titan enhances this information with AI-powered summaries that highlight key terms in lengthy documents, such as conversion conditions for the company’s notes, leverage and coverage ratios in its credit agreement, and the main obligations and covenants in merger contracts. Users can also review disclosures related to executive compensation arrangements, transition agreements and other governance topics reported under Item 5.02 of Form 8-K.
By combining real-time updates from EDGAR with AI-generated explanations, the Halozyme filings page helps readers quickly locate and interpret the sections of 10-Ks, 10-Qs, 8-Ks and related exhibits that are most relevant to their analysis of HALO stock.
Halozyme Therapeutics, Inc. President and CEO Helen Torley, who is also a director, reported a series of option exercises and related stock sales in early February 2026 under a pre-arranged Rule 10b5-1 trading plan adopted on March 21, 2025.
On February 3–5, 2026, she exercised company stock options at an exercise price of $12.07 per share and sold the resulting common shares in multiple transactions at weighted average prices generally in the mid-to-high $70s per share, as detailed in the price ranges disclosed for each trade.
Following these transactions, she directly held 708,719 shares of Halozyme common stock and 201,923 options to purchase common stock, with the options originally granted on February 22, 2017 and exercisable over a four-year vesting schedule.
A shareholder of Halozyme Therapeutics, Inc. filed a Form 144 notice to sell 150,000 shares of common stock through J.P. Morgan Securities on the NASDAQ, with an approximate sale date of 02/03/2026. The filing lists an aggregate market value of $11,167,500 for these shares and notes that 117,597,000 shares of common stock were outstanding. The shares to be sold were acquired on 02/03/2026 via a stock option exercise paid in cash. The same shareholder previously sold multiple blocks of Halozyme common stock in November and December 2025, including 20,000-share sales on several November dates and 16,569 shares on 12/01/2025 with reported gross proceeds for each transaction.
Halozyme Therapeutics provides preliminary, unaudited estimates for its 2025 results, including total revenue between $1,385 million and $1,400 million. The company estimates 2025 royalties of $865 million to $870 million, product sales of $372 million to $377 million, and collaboration revenue of $148 million to $153 million. These figures were shared in connection with 2026 financial guidance and remain subject to completion of year-end financial closing procedures.
Halozyme Therapeutics, Inc. reported that it has entered into a Transition and Release Agreement with its Senior Vice President and Chief Financial Officer, Nicole LaBrosse, in connection with her previously announced planned departure. She will continue as CFO until the earlier of the hiring of a new CFO, March 30, 2026, or an earlier date set by the company, after which she will leave to pursue another opportunity.
Under the agreement, Ms. LaBrosse is eligible to receive her 2025 annual bonus at 120% target-level individual performance, cash severance consistent with a termination not for cause, potential pro-rated 2026 bonus, accelerated vesting of certain equity awards if her separation occurs before February 28, 2026, and an extended one-year post-termination exercise window for vested stock options. If a Change in Control occurs within one year after her separation, all then-unvested options will vest, and the company will cover the cost of COBRA healthcare continuation for one year following her separation date.
Halozyme Therapeutics, Inc. is registering 219,336 shares of its common stock, par value $0.001 per share, for issuance upon exercise of stock options outstanding under the Elektrofi, Inc. 2015 Equity Incentive Plan, as amended. These options were assumed in connection with Halozyme’s acquisition of Elektrofi, Inc., which closed pursuant to a merger in which Elektrofi became a wholly owned subsidiary of Halozyme. The filing also confirms that Halozyme has incorporated a broad set of previously filed reports and describes its standard Delaware-law indemnification protections for directors and officers, including charter and bylaw provisions, individual indemnification agreements, and related insurance coverage.
Halozyme Therapeutics (HALO) insider activity: The President and CEO, who also serves as a director, exercised stock options and sold shares under a Rule 10b5-1 trading plan adopted on March 21, 2025.
Across November 10–12, 2025, the executive exercised 60,000 options at $8.11 per share (20,000 each day) and sold 60,000 shares in multiple tranches. Reported weighted average sales prices included $68.714 and $69.3 on November 10; $67.892, $68.795, and $69.731 on November 11; and $70.218, $71.089, and $71.667 on November 12. The sales reflect shares acquired from option exercises, with the underlying options having a ten‑year term expiring in February 2026.
Following the reported transactions, the executive beneficially owned 733,719 shares directly. Remaining options beneficially owned declined to 16,569 after these exercises.
Halozyme Therapeutics (HALO) reported an insider transaction by a director. On 11/10/2025, the director sold 2,000 shares of common stock at $68.48 per share under a Rule 10b5-1 trading plan adopted on May 29, 2025. Following the sale, the director beneficially owns 42,952 shares, held directly.
Halozyme Therapeutics completed a $1.5 billion convertible note financing, split between $750.0 million of 0% Convertible Senior Notes due 2031 and $750.0 million of 0.875% Convertible Senior Notes due 2032, including full exercise of the Initial Purchasers’ options.
The company received net proceeds of approximately $1.47 billion. It used about $182.7 million for capped call transactions and paid approximately $1.020 billion in cash to repurchase portions of its 2027 and 2028 convertible notes. The remaining proceeds are earmarked for general corporate purposes, potential acquisitions and strategic transactions, and potential future note repurchases or repayment at maturity.
The notes are convertible at an initial rate of 11.4683 shares per $1,000 (conversion price ~$87.20). The 2032 notes bear 0.875% interest, paid semi‑annually starting May 15, 2026; the 2031 notes bear no regular interest. Capped calls carry an initial cap price of $136.78 per share. Holders have customary conversion windows and protections, including Fundamental Change repurchase rights and Make‑Whole adjustments, under the new indentures.
Halozyme Therapeutics announced the pricing of two convertible senior note offerings to institutional investors under Rule 144A. The company plans to issue $650.0 million aggregate principal amount of notes due 2031 and $650.0 million due 2032. Initial purchasers received a 13-day option to buy up to an additional $100.0 million of each series. The notes are being offered only to persons reasonably believed to be qualified institutional buyers.
A press release with additional details was furnished as Exhibit 99.1.
Halozyme Therapeutics (HALO) amended its credit facility, extending and upsizing its revolving line to
The company also announced proposed convertible offerings:
FAQ
What is the current stock price of Halozyme Thrp (HALO)?
What is the market cap of Halozyme Thrp (HALO)?
